Precigen operates as a commercial-stage biopharmaceutical company based in Germantown, Maryland. Its flagship product, PAPZIMEOS (zopapogene imadenovec-drba), became the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), a rare condition involving repeated airway tumors that previously required multiple surgeries. The therapy stems from the company’s AdenoVerse immunotherapy platform and showed a 51% complete response rate in its key trial while securing coverage for more than 315 million lives in the U.S. The pipeline also includes PRGN-2009 for HPV-related cancers and UltraCAR-T programs targeting immuno-oncology, autoimmune conditions, and infectious diseases. In September 2026 the company earned FDA Platform Technology Designation for AdenoVerse along with seven years of orphan drug exclusivity for PAPZIMEOS.
Shares dropped from $6.385 on October 16 to $4.30 on November 16, representing a decline of roughly 32.7%. Sharp single-day losses in early November highlighted the pressure from competitive news and sector-wide moves. Over the full quarter the picture looks similar, with shares near $6.55 in mid-August and down about 34% since then after reaching roughly $8.56 in late September. The period featured an initial climb into September followed by a reversal that wiped out most of the earlier yearly gains. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several elements overlapped to push the stock lower. Competitive developments stood out first: a rival RRP treatment received conditional FDA approval that still requires a confirmatory study. Management viewed the news as expected and pointed to PAPZIMEOS’s distinct profile, yet questions about future market share surfaced anyway. Broader sector sentiment added pressure after disappointing clinical data from a large-cap peer such as Amgen (AMGN) and renewed macroeconomic worries hit high-beta biotechnology names. Even with solid third-quarter numbers—PAPZIMEOS revenue of $72.9 million, up 37% from the prior quarter, net income of $35.8 million, and $11.9 million in operating cash flow—the lack of formal fourth-quarter guidance and roughly $100 million in debt may have encouraged profit-taking. From what I see, competition, sector rotation, and post-earnings positioning outweighed the improving fundamentals in the near term.
The three-month view shows a steep rise followed by an equally steep reversal. Through September, shares moved toward the $8.50–$9.00 area on accelerating PAPZIMEOS uptake, the FDA Platform Technology Designation, orphan drug exclusivity, and rising profitability. October and November brought competitive concerns and reduced risk appetite for biotech, reversing those advances. The net result is a roughly 34% decline over three months, leaving the stock well below its 52-week high even as reported results improved. This appears to reflect a market adjustment to growth expectations rather than any weakening in the underlying numbers.
Investors following Precigen will likely track several upcoming items. The next R&D Day should feature Phase 2 data for PRGN-2009 in HPV-associated oropharyngeal cancer, offering insight into the wider AdenoVerse pipeline. The European Medicines Agency is still reviewing the Marketing Authorization Application for PAPZIMEOS, so any decision on ex-U.S. commercialization could influence the growth story. Launch progress for the competing RRP therapy remains important, as does fourth-quarter revenue performance given the decision to skip formal quarterly guidance. Other points include redosing-study enrollment, plans for pediatric and geographic expansion, and balance-sheet management with roughly $100 million in debt outstanding. These factors will help clarify whether the recent price adjustment is mainly short-term sentiment or a longer-term shift in expectations. I’m watching this closely with the help of Tickeron’s AI Trend Prediction Engine for broader sector context.
In my own research I often turn to Tickeron’s automated resources to cross-check signals and compare performance across biotech names. The Trending AI Robots section, for instance, curates top-performing bots that trade thousands of tickers and highlights those showing relevance in current market conditions. It provides a straightforward way to review data-driven approaches without sorting through the entire catalog, which helps when evaluating volatile sectors like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The RSI Oscillator for PGEN moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 28 of the 32 cases the stock moved higher. This puts the odds of a move higher at 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 88 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for PGEN entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (36.727) is normal, around the industry mean (3.586). P/E Ratio (-4.178) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology